This preprint is under consideration at Nanoscale Research Letters. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Nano Express
Fe(II) and tannic acid-cloake MOF as carrier of artemisinin for supply of ferrous ions to enhance treatment of triple-negative breast cancer
Dejun Ding
Weifang Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7809-7963
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Suppression of tumor development by inducing ferroptosis may provide a potential remedy for triple-negative breast cancer (TNBC), which is sensitive to intracellular oxidative imbalance. Recently, artemisinin (ART) and its derivatives have been investigated as potential anticancer agents for the treatment of highly aggressive cancers via the induction of ferroptosis by iron-mediated cleavage of the endoperoxide bridge. Poor water solubility and insufficient availability of intracellular ferrous ions, limit the further application of ART in antitumor therapy. In this study, ferrous-supply nanocarrier was constructed based on tannic acid (TA) and ferrous ion (Fe2+)-coated on the zeolitic imidazolate framework-8(ZIF) with ART encapsulated (TA-Fe/[email protected]). via supramolecular coordination. Following the internalization of the as-prepared nano-system in cells, acidic degradation of the vehicles would facilitate the release of ART and accumulation of Fe2+. The results revealed that the newly developed nano-drug system displayed a high level of intracellular ROS generation, and markedly enhanced ferroptosis. This work provides a novel approach to enhance the potency of ferroptotic nanomedicine and new directions for TBNC therapy.
Keywords
Artemisinin, Ferroptosis, Triple-negative breast cancer, Metal organic frameworks, Reactive oxygen species,
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 25 Sep, 2020
No community comments so far
Editorial decision: Major revision
On 29 Oct, 2020
Review #1 received
Received 01 Oct, 2020
Reviewer #4 agreed
On 30 Sep, 2020
Review #2 received
Received 29 Sep, 2020
Reviewers invited
Invitations sent on 27 Sep, 2020
Reviewer #1 agreed
On 27 Sep, 2020
Reviewer #2 agreed
On 27 Sep, 2020
Reviewer #3 agreed
On 27 Sep, 2020
Editor assigned
On 14 Sep, 2020
First submitted
On 13 Sep, 2020
Submission checks complete
On 13 Sep, 2020
Editor invited
On 13 Sep, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Nanoscience
Learn more about our company.
This preprint is under consideration at Nanoscale Research Letters. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Nano Express
Fe(II) and tannic acid-cloake MOF as carrier of artemisinin for supply of ferrous ions to enhance treatment of triple-negative breast cancer
Dejun Ding
Weifang Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7809-7963
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 25 Sep, 2020
No community comments so far
Editorial decision: Major revision
On 29 Oct, 2020
Review #1 received
Received 01 Oct, 2020
Reviewer #4 agreed
On 30 Sep, 2020
Review #2 received
Received 29 Sep, 2020
Reviewers invited
Invitations sent on 27 Sep, 2020
Reviewer #1 agreed
On 27 Sep, 2020
Reviewer #2 agreed
On 27 Sep, 2020
Reviewer #3 agreed
On 27 Sep, 2020
Editor assigned
On 14 Sep, 2020
First submitted
On 13 Sep, 2020
Submission checks complete
On 13 Sep, 2020
Editor invited
On 13 Sep, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Nanoscience
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Suppression of tumor development by inducing ferroptosis may provide a potential remedy for triple-negative breast cancer (TNBC), which is sensitive to intracellular oxidative imbalance. Recently, artemisinin (ART) and its derivatives have been investigated as potential anticancer agents for the treatment of highly aggressive cancers via the induction of ferroptosis by iron-mediated cleavage of the endoperoxide bridge. Poor water solubility and insufficient availability of intracellular ferrous ions, limit the further application of ART in antitumor therapy. In this study, ferrous-supply nanocarrier was constructed based on tannic acid (TA) and ferrous ion (Fe2+)-coated on the zeolitic imidazolate framework-8(ZIF) with ART encapsulated (TA-Fe/[email protected]). via supramolecular coordination. Following the internalization of the as-prepared nano-system in cells, acidic degradation of the vehicles would facilitate the release of ART and accumulation of Fe2+. The results revealed that the newly developed nano-drug system displayed a high level of intracellular ROS generation, and markedly enhanced ferroptosis. This work provides a novel approach to enhance the potency of ferroptotic nanomedicine and new directions for TBNC therapy.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6